Analyzing blood and tumor markers to predict response to immunotherapy in advanced cancer
Official title: Analysis of PD-L1, TMB, CTDNA in Immunotherapy Response Monitoring and Prediction in Advancer Lung Cancer Treatment.
Run by Gene Solutions · NCT06227728 · Data updated 2026-11-12
This study is testing if blood and tumor markers can help predict how well people with advanced cancer will respond to immunotherapy treatments.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Gene Solutions Industry-sponsored |
| Drugs / interventions | Durvalumab, chemotherapy |
| Locations | 2 sites (Ho Chi Minh City, Hồ Chí Minh and 1 other locations) |
| Status | Recruiting |
| Started | March 22, 2024 |
| Main results expected | December 1, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | January 16, 2026 |
| Trial ID | NCT06227728 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older diagnosed with stage IV non-small cell lung cancer, breast cancer, colorectal cancer, gastric cancer, or liver cancer who are eligible for immune checkpoint inhibitors.
✕Probably not a fit
Patients who have already started immunotherapy or chemotherapy prior to enrollment will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational clinical trial aims to investigate the dynamics of circulating tumor DNA (ctDNA) alongside conventional tumor markers such as PD-L1, tumor mutational burden (TMB), and microsatellite instability (MSI) to predict and monitor responses to immune checkpoint inhibitors (ICIs) in patients with stage IV cancer. Participants will provide blood samples and tumor tissue for analysis at multiple time points, allowing researchers to assess changes over the course of treatment. The study will follow patients for two years, collecting demographic and medical history data to evaluate the effectiveness of these biomarkers in predicting treatment outcomes.
Why it matters
Potential benefit: If successful, this study could provide a more accurate method for predicting patient responses to immunotherapy, potentially leading to personalized treatment plans.
How similar studies have gone: Other studies have shown promise in using ctDNA and tumor markers to predict responses to immunotherapy, suggesting that this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years and older, both genders. * Patients are diagnosed with stage IV cancer (lung, colorectal, breast, liver, gastric…) and indicated for ICI (first or second line). Concurrent chemotherapy with ICI is allowed. * FFPE/FNA sample is available. * Compliant with treatment protocol. * Patients consented to participate in the study. Exclusion Criteria: * Patients already started ICI before enrollment. * Consolidation ICI (eg. Durvalumab). * Patients already started chemotherapy before enrollment. * Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol. * Patients did not agree to participate in the studies.
Where it's running
-
University of Medicine and Pharmacy at HCMC
Ho Chi Minh City, Hồ Chí Minh, Vietnam Recruiting -
Medical Genetics Institute
Ho Chi Minh City, Vietnam Not yet recruiting
Study contacts
- Principal investigator: Sinh D Nguyen — Mgi
- Study coordinator: Lan NL Tu, PHD
- Email: lantu@genesolutions.vn
- Phone: +84888843489
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing MGC026 in patients with advanced solid tumors
This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.
-
First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors
This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.
-
Evaluating zanidatamab for HER2-expressing tumors
This study is testing a new drug called zanidatamab to see if it can help people with certain types of cancer that have high levels of HER2 and who have already tried other treatments without success.
-
Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues
This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.
-
Evaluating AGX101 for advanced solid tumors
This study is testing a new drug called AGX101 to see if it can help people with advanced solid tumors who haven't had success with other treatments.
-
Targeting CEA with CAR-T cells for advanced solid tumors
This study is testing a new type of CAR-T cell treatment for people with advanced solid tumors to see if it's safe and how well it works.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.